Rubicon Project

Rubicon Biotechnology is a pre-clinical stage biopharmaceutical company focused on developing targeted therapies for conditions with high unmet medical needs, particularly in the areas of tissue damage and oncology. The company's core technology platform utilizes a proprietary fusion protein, Fv-Hsp70, which combines a single-chain antibody fragment with Heat Shock Protein 70 to target and protect stressed or damaged cells. By binding to phosphatidylserine exposed on the surface of compromised cells, Rubicon's therapeutic candidates aim to mitigate ischemia-reperfusion injury and modulate immune responses in the tumor microenvironment. The company is currently advancing programs for traumatic brain injury, stroke, and various solid tumors.